MEDICA2024 | YHLO Showcases Biochemistry-Immunoassay Analyzer
On November 11, 2024, the world’s medical community turned its attention to Düsseldorf, Germany, for the annual premier event in the healthcare industry, MEDICA. As one of China’s leading companies in in vitro diagnostics (IVD), YHLO showcased its cutting-edge iFlash series chemiluminescence immunoassay analyzers and, for the first time in Europe, introduced its new biochemistry-immunoassay integrated analyzer, drawing significant attention from industry professionals.
YHLO’s iFlash series chemiluminescence immunoassay analyzers, highly acclaimed in the industry for their exceptional accuracy and rapid processing speed, were prominently featured at the exhibition. In addition to its leading self-immunity diagnostic products, YHLO presented its new biochemistry-immunoassay integrated analyzer along with a comprehensive suite of over 100 testing assays. As a major player in China’s IVD industry, YHLO offers a wide array of testing solutions covering self-immunity, infectious disease, reproductive health, liver disease, respiratory conditions, and cardiovascular diagnostics, among others. The new integrated analyzer provides laboratories with more flexible testing options.
The unveiling of YHLO’s biochemistry-immunoassay integrated analyzer at MEDICA in Germany not only highlights the company’s strong technical expertise in IVD technology but also underscores YHLO’s commitment to expanding its presence in the European market. Europe, recognized for its rich academic research landscape, holds strategic value for YHLO. Guided by a "sales through academic leadership" approach, YHLO has built a robust network of collaborations with key laboratories and academic institutions across Europe, dedicated to advancing research and academic exchange together.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
YHLO × Sanofi — Building a Type 1 Diabetes Ecosystem Together
YHLO joined hands with Sanofi to launch the China Type 1 Diabetes Ecosystem Co-construction Alliance during the 8th China International Import Expo
2025-11-06
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
